Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

Key Findings

Trifluridine/tipiracil (FTD/TPI) showed improved progression-free and overall survival for pre-treated metastatic colorectal cancer patients. The treatment also maintained quality of life for the patients.

Study Details

The TALLISUR trial in Germany assessed the efficacy, safety, and quality of life in patients with pre-treated metastatic colorectal cancer receiving either FTD/TPI or best supportive care. The study used EORTC QLQ-C30 and EQ-5D-5L questionnaires to evaluate quality of life, in addition to assessing overall survival, progression-free survival, and safety.

Subgroup Analysis Results

It was found that patients with a lower metastatic burden and indolent disease had more favorable outcomes when treated with FTD/TPI.

Clinical Implications

The study highlights the importance of considering baseline characteristics and prognostic subgroups when assessing treatment outcomes for metastatic colorectal cancer patients.

Clinical Trial Registration

EudraCT-Number 2017-000292-83, first registration 19/06/2017

Important Message: Clinical trials play a crucial role in the development of safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical protocols and research into a single knowledge base for clinicians, aiming to extend the benefits of clinical trials into everyday medical practice.